Alnylam Pharmaceuticals
ALNY
ALNY
495 hedge funds and large institutions have $22.6B invested in Alnylam Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 95 funds opening new positions, 166 increasing their positions, 159 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
4% more repeat investments, than reductions
Existing positions increased: 166 | Existing positions reduced: 159
0.3% less ownership
Funds ownership: 94.21% → 93.91% (-0.3%)
17% less call options, than puts
Call options by funds: $267M | Put options by funds: $321M
Holders
495
Holding in Top 10
6
Calls
$267M
Puts
$321M
Top Buyers
| 1 | +$162M | |
| 2 | +$150M | |
| 3 | +$93.6M | |
| 4 |
Morgan Stanley
New York
|
+$77.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$54.9M |
Top Sellers
| 1 | -$229M | |
| 2 | -$185M | |
| 3 | -$110M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$84.4M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$67.9M |